DR. STEVEN KEITH BURKE, M.D.
Osteopathic Medicine at 2 Ave, Waltham, MA
License number
Massachusetts 70798
Category
Osteopathic Medicine
Type
Gastroenterology
Address
Address
2
153 2Nd Ave, Waltham, MA 02451
82 Willis Rd, North Sudbury, MA 01776
82 Willis Rd, North Sudbury, MA 01776
Phone
(781) 434-3439
(617) 768-9874 (Fax)
(978) 443-6350
(617) 768-9874 (Fax)
(978) 443-6350
Personal information
See more information about STEVEN KEITH BURKE at radaris.comName
Address
Phone
55 Fottler Rd APT 57, Hingham, MA 02043
42 Tewksbury St, Lawrence, MA 01843
402 Mariners Hill Dr, Marshfield, MA 02050
297 Lexington St, Watertown, MA 02472
2 Longfellow Rd, Cambridge, MA 02138
Professional information
Steven Keith Burke, Waltham MA
Specialties:
Internal Medicine, Gastroenterology
Work:
Genzyme
153 2Nd Ave, Waltham, MA 02451 Healthcare Analytics
77 4Th Ave, Waltham, MA 02451
153 2Nd Ave, Waltham, MA 02451 Healthcare Analytics
77 4Th Ave, Waltham, MA 02451
Education:
Cornell University (1987)
Method For Treating Hypercholesterolemia With Polyallylamine Polymers
US Patent:
6423754, Jul 23, 2002
Filed:
Nov 26, 1997
Appl. No.:
08/979096
Inventors:
Stephen Randall Holmes-Farley - Arlington MA
Steven K. Burke - Sudbury MA
Dennis I. Goldberg - Sudbury MA
Steven K. Burke - Sudbury MA
Dennis I. Goldberg - Sudbury MA
Assignee:
GelTex Pharmaceuticals, Inc. - Waltham MA
International Classification:
A61P 910
US Classification:
514824, 424 7818, 424 7827
Abstract:
A method for removing bile salts from a patient that includes administering to the patient a therapeutically effective amount of a non-absorbable amine polymer characterized by a repeat unit having the formula: and salts thereof, where n is a positive integer and x is zero or an integer between 1 and about 4.
Methods Of Treating Syndrome X With Aliphatic Polyamines
US Patent:
2008008, Apr 10, 2008
Filed:
Jun 28, 2007
Appl. No.:
11/823853
Inventors:
Steven Burke - Sudbury MA, US
Joanne Donovan - Needham MA, US
Joanne Donovan - Needham MA, US
International Classification:
A61K 31/336, A61K 31/675, A61K 31/70
US Classification:
514052000, 514475000, 514089000
Abstract:
The invention relates to a method for treating Syndrome X, or inhibiting the onset of symptoms of Syndrome X in a patient, and includes administering a therapeutically effective amount of a salt of at least one alkylated and cross-linked polymer, or a copolymer thereof, the polymer salt formed as a product of the reaction of one or more polymers, or salts and copolymers thereof, having a repeat unit that is essentially:
where n is a positive integer and each R, independently, is H or a C-Calkyl group; at least one aliphatic alkylating agent; and a cross-linking agent. Long term administration of the cross-linked polyamine salts of the invention increases HDL levels and decreases LDL levels in patients. The invention also provides for administration of the polymer salt colesevelam, in combination with an HMG-CoA reductase inhibitor; the combined administration is effective in further lowering serum total-cholesterol and LDL-cholesterol levels beyond that achieved by either agent alone.
Method For Treating Gout And Binding Uric Acid
US Patent:
2008011, May 15, 2008
Filed:
Jun 18, 2007
Appl. No.:
11/820292
Inventors:
Stephen Randall Holmes-Farley - Arlington MA, US
Steven K. Burke - Sudbury MA, US
Steven K. Burke - Sudbury MA, US
International Classification:
A61K 31/785, A61K 31/787, C08G 79/02, C08L 85/02
US Classification:
424 7827, 525540, 525538
Abstract:
A method for treating gout and/or reducing serum uric acid levels in a patient is disclosed that includes administering to the patient a therapeutically effective amount of an amine polymer, for example, an aliphatic amine polymer. In one embodiment, the polymer binds to uric acid or a precursor thereof. Examples of polymers useful in an embodiment of the invention include sevelamer hydrochloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula:and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that binds serum uric acid in a patient.
Method For Treating Hypercholesterolemia With Polyallylamine Polymers
US Patent:
2003008, May 8, 2003
Filed:
May 29, 2002
Appl. No.:
10/158207
Inventors:
Stephen Holmes-Farley - Arlington MA, US
W. Mandeville - Lynnfield MA, US
Steven Burke - Sudbury MA, US
Dennis Goldberg - Sudbury MA, US
W. Mandeville - Lynnfield MA, US
Steven Burke - Sudbury MA, US
Dennis Goldberg - Sudbury MA, US
Assignee:
GelTex Pharmaceuticals, Inc. - Waltham MA
International Classification:
A61K031/785
US Classification:
424/078270
Abstract:
A method for removing bile salts from a patient that includes administering to the patient a therapeutically effective amount of a non-absorbable amine polymers characterized by a repeat unit having the formula:
and salts thereof, where n is a positive integer and x is zero or an integer between 1 and about 4.
Method For Treating Gout And Binding Uric Acid
US Patent:
2003003, Feb 27, 2003
Filed:
Apr 17, 2002
Appl. No.:
10/125685
Inventors:
Stephen Holmes-Farley - Arlington MA, US
Steven Burke - Sudbury MA, US
Steven Burke - Sudbury MA, US
Assignee:
GelTex Pharmaceutical, Inc. - Waltham MA
International Classification:
A61K031/785
US Classification:
424/078350
Abstract:
A method for treating gout and/or reducing serum uric acid levels in a patient is disclosed that includes administering to the patient a therapeutically effective amount of an amine polymer, for example, an aliphatic amine polymer. In one embodiment, the polymer binds to uric acid or a precursor thereof. Examples of polymers useful in an embodiment of the invention include sevelamer hydrochloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula:
and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that binds serum uric acid in a patient.
Method For Treating Gout And Reducing Serum Uric Acid
US Patent:
2002018, Dec 12, 2002
Filed:
Apr 17, 2002
Appl. No.:
10/125793
Inventors:
Stephen Holmes-Farley - Arlington MA, US
Steven Burke - Sudbury MA, US
Steven Burke - Sudbury MA, US
Assignee:
GelTex Pharmaceutical, Inc. - Waltham MA
International Classification:
A61K031/785, A61K031/74
US Classification:
424/078310
Abstract:
A method for treating gout and/or reducing serum uric acid levels in a patient is disclosed that includes administering to the patient a therapeutically effective amount of an amine polymer; for example, an aliphatic amine polymer. Examples of polymers useful in the invention are sevelamer hydrogen chloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula:
and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that reduces serum uric acid levels in a patient.
Low Salt Forms Of Polyallylamine
US Patent:
8377428, Feb 19, 2013
Filed:
Apr 21, 2009
Appl. No.:
12/427127
Inventors:
John S. Petersen - Acton MA, US
Steven K. Burke - Sudbury MA, US
Stephen Randall Holmes-Farley - Arlington MA, US
Steven K. Burke - Sudbury MA, US
Stephen Randall Holmes-Farley - Arlington MA, US
Assignee:
Genzyme Corporation - Cambridge MA
International Classification:
A61K 31/74
US Classification:
424 781
Abstract:
Disclosed is a pharmaceutical composition comprising a stable polyallylamine hydrochloride polymer in which between about 4% to about 12% by weight of the polymer is a chloride anion and a pharmaceutically acceptable carrier or diluent.
Once A Day Formulation For Phosphate Binders
US Patent:
2009030, Dec 10, 2009
Filed:
May 14, 2009
Appl. No.:
12/466004
Inventors:
Steven K. Burke - Sudbury MA, US
Assignee:
GENZYME CORPORATION - Cambridge MA
International Classification:
A61K 31/785, A61P 5/00
US Classification:
424 7835
Abstract:
A method for reducing serum phosphate in a subject in need thereof comprising administering once per day to said subject a phosphate binder, wherein the phosphate binder has a phosphate binding capacity of at least 52 mmole.
Low Salt Forms Of Polyallylamine
US Patent:
7541024, Jun 2, 2009
Filed:
Apr 17, 2002
Appl. No.:
10/125684
Inventors:
John S. Petersen - Acton MA, US
Steven K. Burke - Sudbury MA, US
Stephen Randall Holmes-Farley - Arlington MA, US
Steven K. Burke - Sudbury MA, US
Stephen Randall Holmes-Farley - Arlington MA, US
Assignee:
Genzyme Corporation - Cambridge MA
International Classification:
A61K 31/74
US Classification:
424 781
Abstract:
Disclosed is a pharmaceutical composition comprising a stable polyallylamine hydrochloride polymer in which between about 4% to about 12% by weight of the polymer is a chloride anion and a pharmaceutically acceptable carrier or diluent.